Skip to search formSkip to main contentSkip to account menu

ATM Kinase Inhibitor AZD0156

Known as: AZD0156 
An orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 271: The role of ATM and DNA-PK in responding to AZD6738-induced damage in pancreatic ductal adenocarcinoma cells
Therapeutic targeting of the DNA damage response (DDR) has the potential to improve the poor survival outcomes of pancreatic… 
2018
2018
Abstract 331: Therapeutic co-targeting of WEE1 and ATM has synergistic effects and contributes to downregulation of PD-L1 expression in pancreatic cancer
Background: Currently, targeting DNA damage response (DDR) is one of strategies for new cancer drug development. DDR pathway… 
2018
2018
Abstract 323: DNA damage response (DDR)-targeting strategy by targeting WEE1 and or ATM/ATR works in biliary tract cancer
Background: Currently, targeting DNA damage response (DDR) is one strategy for new cancer drug development. DDR pathway involves… 
2016
2016
Identifying high quality, potent and selective inhibitors of ATM kinase: Discovery of AZD0156
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)